Xtant Medical Holdings, Inc. raised revenue guidance for the year 2023. The company raises its expectation for full year 2023 revenue to $75 million to $77 million, up from the Company?s prior guidance of $73 million to $75 million. The revised guidance range represents annual revenue growth of approximately 29% to 33% compared to full year 2022 revenue, and excludes any potential contributions from the Surgalign transaction, if and when that transaction closes.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.8 USD | -1.27% | -9.11% | -29.20% |
04-30 | Xtant Medical Holdings, Inc. Announces Launch of SimpliGraft and SimpliMax for Chronic and Acute Wounds | CI |
04-01 | Xtant Medical Files $150 Million Mixed Shelf; Shares Fall | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-29.20% | 106M | |
+8.38% | 126B | |
-6.68% | 10.96B | |
+1.56% | 8.97B | |
+36.32% | 5.56B | |
-21.55% | 4.99B | |
+8.20% | 3.44B | |
-7.69% | 2.8B | |
-8.42% | 2.18B | |
-5.20% | 2.16B |
- Stock Market
- Equities
- XTNT Stock
- News Xtant Medical Holdings, Inc.
- Xtant Medical Holdings, Inc. Raises Revenue Guidance for the Year 2023